# Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

> **NCT00407459** · PHASE2 · COMPLETED · sponsor: **Armando Santoro, MD** · enrollment: 77 (actual)

## Conditions studied

- Mesothelioma

## Interventions

- **DRUG:** Bevacizumab, Pemetrexed, Carboplatin

## Key facts

- **NCT ID:** NCT00407459
- **Lead sponsor:** Armando Santoro, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2011-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407459, "Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00407459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*